Loading clinical trials...

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation

NCT00136903•Mesoblast, Inc.

View on ClinicalTrials.gov

Summary

To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.

Detailed Description

Protocol 260 - Participants will be randomized with equal probability to the treatment arms (2 million cells/kilogram (kg) of Prochymal® or 8 million cells/kg of Prochymal®) using a stratified block design. The stratification factor is acute GVHD grade. For the purpose of stratification, the GVHD grades are II and III-IV. Treatment with investigational agent will be administered on study Days 1 and 4. Participants will be followed for safety and efficacy until Day 28 after initiation of treatment with the investigational agent, or until withdrawal or death, whichever occurs first. Protocol 261- This study is designed as a long-term safety follow-up of participants who take part in the preceding clinical study of Prochymal® (Protocol 260) for the treatment of acute GVHD. Participants will be enrolled in Study 261 upon completion of the preceding Study 260.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participant must be 18 to 70 years of age inclusive.
•If female and of child-bearing age, participant must be non-pregnant, not breast feeding, and use adequate contraception. Males must use adequate contraception.
•Participant must have newly diagnosed, Grade II-IV acute GVHD requiring therapy. Biopsy for confirmation of GVHD is not mandatory, but is recommended when feasible. Enrollment should not be delayed awaiting biopsy results.
•Participant must have received either full or reduced intensity myeloablative regimens followed by an allogeneic hematopoietic stem cell transplant using bone marrow, peripheral blood stem cell, or cord blood, including donor lymphocyte infusion (DLI).
•Participant must have minimal renal and hepatic function as defined by:
•\* Calculated creatinine clearance (CLcr) of \> 30 mL/min using the Cockroft-Gault equation.
•Participant must be available for all specified assessments at the study site through study Day 28.
•Participant must provide written informed consent and authorization for use and disclosure of protected health information (PHI).

Exclusion Criteria

•Participant has received previous treatment for Grade II-IV acute GVHD (except as noted in Criterion 2).
•Participant has been treated for GVHD with methylprednisolone, \> 2mg/kg/day, for more than 72 hours prior to receiving Prochymal®.
•Participant has uncontrolled alcohol or substance abuse within 6 months of randomization.
•Participant has received an investigational agent (not approved by food and drug administration (FDA) for marketed use in any indication) within 30 days of randomization. Participant may not receive an investigational agent during the 28-day study period.
•Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant (e.g., uncontrolled infection, right heart failure, pulmonary hypertension, etc.).
•Participant has unstable arrhythmia.
•Participant is unwilling to sign consent form for the long-term follow-up study, Protocol 261.
•Participant has a known allergy to bovine or porcine products.
•Participant had received transplant for a solid tumor disease.

Locations (9)

St. Francis Hospital

Indianapolis, Indiana, United States

Kansas City Cancer Centers - BMT

Kansas City, Missouri, United States

The Cancer Center at Hackensack University

Hackensack, New Jersey, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Mt. Sinai Hospital

New York, New York, United States

University of Rochester

Rochester, New York, United States

New York Medical College

Valhalla, New York, United States

MD Anderson Cancer Center

Houston, Texas, United States

Medical College of Wisconsin, FEC

Milwaukee, Wisconsin, United States

Key Dates

Start Date

April 27, 2005

Primary Completion Date

July 28, 2006

Completion Date

July 14, 2008

Last Updated

January 31, 2022

Enrollment

ACTUAL participants

Conditions

Graft Vs Host Disease

Interventions

Prochymal® - 2 Million cells/kg

DRUG

Prochymal®- 8 Million cells/kg

DRUG

Methylprednisolone

DRUG

Prednisone

DRUG

Cyclosporine

DRUG

Tacrolimus

DRUG

Mycophenolate Mofetil

DRUG

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

NCT00106925

Graft-versus-leukemiaGraft vs Host Disease+1 more

View study

RECRUITINGPHASE2

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

NCT06450925

Graft Vs Host DiseaseVitamin A Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Inclusion Criteria

Exclusion Criteria

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation